Oculus Innovative Sciences is launching its Dermacyn™ wound treatment product in China by sending samples of the product to hospitals in ten China provinces. Sinopharm, the company in charge of China distribution of the product, also featured Dermacyn at a recent trade show, the New Drugs China Expo sponsored by Health Tech Forum 2008. The product was approved by the SFDA in March of this year to treat acute and chronic wounds including ulcers, cuts, contusions and burns. More details...

Stock Symbol: (NSDQ: OCLS)